Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Mainz Biomed NV (MYNZ : NSDQ)
 
 • Company Description   
Mainz Biomed N.V. develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. Mainz Biomed N.V. is based in BERKELEY, Calif.

Number of Employees: 26

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.00 Daily Weekly Monthly
20 Day Moving Average: 148,717 shares
Shares Outstanding: 3.44 (millions)
Market Capitalization: $6.88 (millions)
Beta: 0.21
52 Week High: $20.08
52 Week Low: $1.34
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.50% -3.26%
12 Week -37.89% -47.76%
Year To Date -53.70% -56.64%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ROBERT KOCH STRASSE 50
-
MAINZ,2M 55129
DEU
ph: 49-6131-554-2860
fax: -
ir@mainzbiomed.com https://mainzbiomed.com
 
 • General Corporate Information   
Officers
Guido Baechler - Chief Executive Officer
William Caragol - Chief Financial Officer
Heiner Dreismann - Director
Chris von Toerne - Director
Hans Hekland - Director

Peer Information
Mainz Biomed NV (CORR.)
Mainz Biomed NV (RSPI)
Mainz Biomed NV (CGXP)
Mainz Biomed NV (BGEN)
Mainz Biomed NV (GTBP)
Mainz Biomed NV (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N5436L119
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 3.44
Most Recent Split Date: 12.00 (0.03:1)
Beta: 0.21
Market Capitalization: $6.88 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-2.00 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-9.20 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.77
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 1.32
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 1.26
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -2,421.81
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - 2.61
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - 0.71
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 0.14
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 12.53
 

Powered by Zacks Investment Research ©